Meeting
2017 ASCO Annual Meeting
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).
Authors
Kaoru Kubota
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
Kaoru Kubota , Tsuneo Shimokawa , Kazuhiko Yamada , Hiroshi Tanaka , Kazuma Kishi , Haruhiro Saito , Yuichi Takiguchi , Yukio Hosomi , Terufumi Kato , Naoyuki Nogami , Takeharu Yamanaka , Noriyuki Masuda , Koshiro Watanabe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000005993
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8534)
DOI
10.1200/JCO.2017.35.15_suppl.8534
Abstract #
8534
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Concurrent chemoradiation (CChRT) with bi-weekly docetaxel and cisplatin and thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC): A phase II study from the Galician Lung Cancer Group.
First Author: Joaquin Casal Rubio
Poster
2015 ASCO Annual Meeting
A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L.
First Author: Takashi Seto
Poster
2013 ASCO Annual Meeting
Long-term results of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer.
First Author: Fumiyoshi Ohyanagi
Poster
2011 ASCO Annual Meeting
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) followed by gemcitabine and carboplatin consolidation in patients with unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657.
First Author: J. Zhang